GLOBAL FIRST “High-Definition Image”: Decoding the “Code of Youth” – LivingPhoenix’s POGMENT Collagen Breakthrough Fills Global Gap
CHENGDU, China, Sept. 11, 2025 /PRNewswire/ -- Recently, LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd. (hereinafter "LivingPhoenix Technology") announced that its independently developed POGMENT triple-helix biomimetic collagen has, for the first time in the world, achieved high-resolution, molecular-level visualization of "collagen fiber bundles" under near-physiological and ultra-low temperature conditions using Cryo-Electron Microscopy (Cryo-EM). This achievement fills an international gap in the...
Lunit Awarded Major National Tender in France, Expanding Access to Breast AI in Public Hospitals
Framework agreement with UniHA enables access to Lunit's breast AI solutions across 1,500+ French public hospitals, in collaboration with Fujifilm SEOUL, South Korea, Sept. 11, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that its breast imaging AI solutions have been selected under...
GLOBAL FIRST “High-Definition Image”: Decoding the “Code of Youth” – LivingPhoenix’s POGMENT Collagen Breakthrough Bridges International Gap
CHENGDU, China, Sept. 11, 2025 /PRNewswire/ -- Recently, LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd., announced that its self-developed POGMENT triple-helix biomimetic collagen has, for the first time globally, achieved high-resolution molecular visualization of "collagen fiber bundles" using Cryo-Electron microscopy (Cryo-EM) under near-physiological and cryogenic conditions. This breakthrough fills the international knowledge gap in understanding collagen's self-assembly mechanism. The result was achieved through collaboration with...
YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC
SHANGHAI, Sept. 11, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $45 million Series B financing led by the AstraZeneca-CICC healthcare investment fund. The proceeds will support the advancement of YolTech's clinical programs and global strategic execution. Dr. Yuxuan Wu, Founder and CEO of YolTech,...
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
SYDNEY, Sept. 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by Professor Sudha Rao at QIMR Berghofer. In this ex vivo study, blood samples from Stage IV HER2-positive metastatic breast cancer (mBC) patients were profiled to evaluate the effect of paxalisib, Kazia's investigational...
Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress (IHC), including three oral presentations on eptinezumab (Vypeti®) and Lu AG09222 (anti-PACAP mAb) New data from the open-label extension of the RESOLUTION trial and the primary results of the SUNSET extension trial will be presented...
HaemaLogiX wins “Most Promising CAR-T Pipeline in APAC” at the Asia Pacific CGT¹ Excellence Awards 2025
SYDNEY, Sept. 11, 2025 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, developing novel immunotherapies for patients with blood cancers and B-cell diseases, was honoured to be awarded the "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT Excellence Awards 2025, held in Singapore last night. HaemaLogiX's Professor Rosanne Dunn accepting an award at...
SynbioTech’s TWK10 Approved to Boost Muscle Strength, The Probiotic Pioneer Marches Toward Southeast Asia Market
BANGKOK, Sept. 11, 2025 /PRNewswire/ -- SynbioTech Inc., ranked among the world's top 20 probiotic suppliers, is the leader in functional probiotics for muscle and joint health, sports, women's wellness, and immune support. Its patented flagship probiotic, Lactiplantibacillus plantarum TWK10®, has earned multiple awards in Europe, the US and Japan, with clinical trials showing increased muscle mass and...
Amaran Biotech Wins Asia-Pacific Biologics CDMO Excellence Award for “Best Fill-Finish”
50-Person Team Demonstrates Taiwan's Biotech Strength HSINCHU, Sept. 11, 2025 /PRNewswire/ -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), was awarded the "Best Fill-Finish" at the 2025 Asia-Pacific Biologics CDMO Excellence Awards held in Singapore on September 10. This honor recognizes Amaran Biotech's leading capabilities in aseptic fill-finish processes and marks an important step for...
XingImaging in partnership with SynuSight was awarded a grant from The Michael J. Fox Foundation to support development of the α-synuclein PET tracer 18F-FD4 for Parkinson’s disease
NEW HAVEN, Conn., Sept. 11, 2025 /PRNewswire/ -- XingImaging in partnership with SynuSight Biotech has received funding of $3.84M from The Michael J. Fox Foundation to conduct studies on 18F-FD4, a specific α-synuclein (α-syn)-targeted PET tracer. Based on prior investigator-initiated trials, the SynuSight Biotech developed technology, showed the potential to become the...
